BR112022013488A2 - Pirazolo-pirimidinas substituídas e seu uso - Google Patents

Pirazolo-pirimidinas substituídas e seu uso

Info

Publication number
BR112022013488A2
BR112022013488A2 BR112022013488A BR112022013488A BR112022013488A2 BR 112022013488 A2 BR112022013488 A2 BR 112022013488A2 BR 112022013488 A BR112022013488 A BR 112022013488A BR 112022013488 A BR112022013488 A BR 112022013488A BR 112022013488 A2 BR112022013488 A2 BR 112022013488A2
Authority
BR
Brazil
Prior art keywords
pyrimidines
substituted pyrazolo
compounds
treatment
pikfyve
Prior art date
Application number
BR112022013488A
Other languages
English (en)
Portuguese (pt)
Inventor
D Rosen Mark
A Galemmo Robert Jr
Liang Weiling
Y Choi Irene
Kopek Brian
Rhodes Jane
Original Assignee
Verge Analytics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Verge Analytics Inc filed Critical Verge Analytics Inc
Publication of BR112022013488A2 publication Critical patent/BR112022013488A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BR112022013488A 2020-01-13 2021-01-12 Pirazolo-pirimidinas substituídas e seu uso BR112022013488A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062960412P 2020-01-13 2020-01-13
US202063074388P 2020-09-03 2020-09-03
PCT/US2021/013077 WO2021146192A1 (en) 2020-01-13 2021-01-12 Substituted pyrazolo-pyrimidines and uses thereof

Publications (1)

Publication Number Publication Date
BR112022013488A2 true BR112022013488A2 (pt) 2022-09-13

Family

ID=74626126

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022013488A BR112022013488A2 (pt) 2020-01-13 2021-01-12 Pirazolo-pirimidinas substituídas e seu uso

Country Status (15)

Country Link
US (1) US12486274B2 (https=)
EP (1) EP4090426B1 (https=)
JP (1) JP7744350B2 (https=)
KR (1) KR20220140515A (https=)
CN (1) CN115209952B (https=)
AU (1) AU2021207804A1 (https=)
BR (1) BR112022013488A2 (https=)
CA (1) CA3167339A1 (https=)
CL (1) CL2022001887A1 (https=)
CO (1) CO2022011258A2 (https=)
IL (1) IL294504A (https=)
MX (1) MX2022008627A (https=)
PH (1) PH12022551623A1 (https=)
TW (1) TWI885039B (https=)
WO (1) WO2021146192A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20220140515A (ko) 2020-01-13 2022-10-18 버지 애널리틱스, 인크. 치환된 피라졸로-피리미딘 및 그의 용도
US20240018151A1 (en) * 2020-10-19 2024-01-18 Tme Therapeutics Llc Novel inhibitors of pikfyve and methods using same
AR126013A1 (es) * 2021-06-01 2023-08-30 Verge Analytics Inc Compuestos heterocíclicos bicíclicos fusionados y usos de los mismos
US20250353852A1 (en) * 2021-12-08 2025-11-20 Kineta, Inc. Compounds and compositions that inhibit pikfyve
WO2024014885A1 (ko) * 2022-07-13 2024-01-18 일동제약(주) 신규 바이사이클릭 헤테로아릴 화합물 및 이의 용도
US20260053813A1 (en) * 2023-02-10 2026-02-26 Verge Analytics, Inc. Substituted Pyrazolo-Pyrimidines and Uses Thereof
CN120093763A (zh) * 2025-03-25 2025-06-06 上海天龙生物科技有限公司 治疗前列腺疾病和腺体类散结节的药物组合物及其应用

Family Cites Families (192)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1087725C (zh) 1994-03-25 2002-07-17 同位素技术有限公司 用氘代方法增强药物效果
US6334997B1 (en) 1994-03-25 2002-01-01 Isotechnika, Inc. Method of using deuterated calcium channel blockers
US6194410B1 (en) 1998-03-11 2001-02-27 Hoffman-La Roche Inc. Pyrazolopyrimidine and pyrazolines and process for preparation thereof
US6423751B1 (en) 1998-07-14 2002-07-23 The Brigham And Women's Hospital, Inc. Upregulation of type III endothelial cell nitric oxide synthase by agents that disrupt actin cytoskeletal organization
WO2000078757A1 (en) 1999-06-17 2000-12-28 Shionogi Bioresearch Corp. Inhibitors of il-12 production
US6384032B1 (en) 1999-06-17 2002-05-07 Shionogi Bioresearch Corp. Inhibitors of IL-12 production
CN1186324C (zh) 2000-04-27 2005-01-26 山之内制药株式会社 稠合杂芳基衍生物
US6680315B2 (en) 2000-06-15 2004-01-20 Synta Pharmaceuticals Corp. Triazine compounds
EP1317450B1 (en) 2000-09-15 2006-11-22 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
NZ526472A (en) 2000-12-21 2004-04-30 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
WO2002088079A2 (en) 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Dual inhibitors of pde 7 and pde 4
JP2005500294A (ja) 2001-06-19 2005-01-06 ブリストル−マイヤーズ　スクイブ　カンパニー ホスホジエステラーゼ７に対するピリミジン阻害剤
PE20030008A1 (es) 2001-06-19 2003-01-22 Bristol Myers Squibb Co Inhibidores duales de pde 7 y pde 4
WO2004017950A2 (en) 2002-08-22 2004-03-04 Piramed Limited Phosphadidylinositol 3,5-biphosphate inhibitors as anti-viral agents
US8673924B2 (en) 2002-09-04 2014-03-18 Merck Sharp & Dohme Corp. Substituted pyrazolo[1,5-a]pyrimidines as cyclin dependent kinase inhibitors
US7550470B2 (en) 2002-12-11 2009-06-23 Merck & Co. Inc. Substituted pyrazolo[1,5-A]pyrimidines as tyrosine kinase inhibitors
JP4564485B2 (ja) 2003-02-28 2010-10-20 帝人ファーマ株式会社 ピラゾロ［１，５−ａ］ピリミジン誘導体
JP2004277337A (ja) 2003-03-14 2004-10-07 Sumitomo Pharmaceut Co Ltd ピラゾロ［１，５−ａ］ピリミジン誘導体
US7700583B2 (en) 2003-04-11 2010-04-20 High Point Pharmaceuticals, Llc 11β-hydroxysteroid dehydrogenase type 1 active compounds
CA2527079A1 (en) 2003-05-29 2005-01-06 Synta Pharmaceuticals, Corp. Heterocyclic compounds for preventing and treating disorders associated with excessive bone loss
CN1826121B (zh) 2003-07-23 2013-05-29 幸讬制药公司 苯基与吡啶基衍生物用于制备调控钙离子释放活化钙离子通道的药物的用途
US20050113379A1 (en) 2003-09-05 2005-05-26 Ping Ge Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands
MXPA06002618A (es) 2003-09-09 2006-06-05 Ono Pharmaceutical Co Antagonistas del factor de liberacion de corticotropina (crf) y compuestos heterobiciclicos.
AU2004289304A1 (en) 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Pyridine compounds
AU2004289303A1 (en) 2003-11-10 2005-05-26 Synta Pharmaceuticals, Corp. Fused heterocyclic compounds
EP1765325A4 (en) 2004-07-01 2009-08-12 Synta Pharmaceuticals Corp HETEROARYL COMPOUNDS SUBSTITUTED IN 2
DE502005008916D1 (de) 2004-07-23 2010-03-11 Medicines Co Leipzig Gmbh Substituierte pyridoä3',2':4,5üthienoä3,2-düpyrimidine und pyridoä3',2':4,5üfuroä3,2-dü-pyrimidine zur verwendung als inhibitoren der pda-4 und/oder tnf-alpha freisetzung
CN101083985A (zh) 2004-09-21 2007-12-05 幸讬制药公司 用于炎症及免疫相关用途的化合物
WO2006053109A1 (en) 2004-11-10 2006-05-18 Synta Pharmaceuticals Corp. Heteroaryl compounds
JP5204489B2 (ja) 2004-11-19 2013-06-05 シンタ ファーマスーティカルズ コーポレイション Ｈｓｐ７０発現を増加するためのビス（チオ‐ヒドラジドアミド）
JP2006160628A (ja) 2004-12-03 2006-06-22 Ishihara Sangyo Kaisha Ltd アデノシンＡ２ａ受容体アゴニストの投与が必要な疾患を治療又は予防するための組成物
KR20070107022A (ko) 2005-01-07 2007-11-06 신타 파마슈티칼스 코프. 염증 및 면역 관련 용도를 위한 화합물
PL1848435T3 (pl) 2005-01-25 2016-08-31 Synta Pharmaceuticals Corp Związki przeciwko zapaleniom i zastosowania związane z odpornością
TWI444187B (zh) 2005-01-25 2014-07-11 Synta Pharmaceuticals Corp 用於炎症及免疫相關用途之噻吩化合物
US7473694B2 (en) 2005-03-17 2009-01-06 Teijin Pharma Limited Pyrazolopyrimidine derivatives or pharmaceutically acceptable salts thereof
WO2006128129A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating cancer
WO2006128172A2 (en) 2005-05-26 2006-11-30 Synta Pharmaceuticals Corp. Method for treating b cell regulated autoimmune disorders
WO2007023382A2 (en) 2005-08-25 2007-03-01 Pfizer Inc. Pyrimidine amino pyrazole compounds, potent kinase inhibitors
RU2008110941A (ru) 2005-08-25 2009-09-27 Ф.Хоффманн-Ля Рош Аг (Ch) ИНГИБИТОРЫ КИНАЗЫ p38 МАР И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
CN101316847A (zh) 2005-10-06 2008-12-03 先灵公司 用作蛋白激酶抑制剂的吡唑并(1,5a)嘧啶化合物
TW200804307A (en) 2005-10-27 2008-01-16 Synta Pharmaceuticals Corp Process for preparing mesylate salts of IL-12 inhibitory compounds
PL1954699T3 (pl) 2005-11-22 2013-01-31 Kudos Pharm Ltd Pochodne pirydo-, pirazo- i pirymidopirymidyny jako inhibitory mTOR
WO2007071688A1 (en) 2005-12-22 2007-06-28 L'oréal Composition for dyeing keratin fibres with a tetraazapentamethine cationic direct dye, a particular oxidation base and a coupler
US20070275960A1 (en) 2006-01-25 2007-11-29 Synta Pharmaceuticals Corp. Phenyl and pyridyl compounds for inflammation and immune-related uses
WO2007087443A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Vinyl-phenyl derivatives for inflammation and immune-related uses
WO2007087441A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Substituted aromatic compounds for inflammation and immune-related uses
CA2639910A1 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Thiazole and thiadiazole compounds for inflammation and immune-related uses
WO2007087442A2 (en) 2006-01-25 2007-08-02 Synta Pharmaceuticals Corp. Substituted biaryl compounds for inflammation and immune-related uses
US20070254926A1 (en) 2006-01-31 2007-11-01 Jun Jiang Pyridylphenyl compounds for inflammation and immune-related uses
EP1829879A1 (en) 2006-02-10 2007-09-05 Cellzome (UK) Ltd. Amino pyrimidine compounds for the treatment of inflammatory disorders
US8119643B2 (en) 2006-03-20 2012-02-21 Synta Pharmaceuticals Corp. Benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses
US8163777B2 (en) 2006-03-23 2012-04-24 Synta Pharmaceuticals Corp. Benzimidazolyl-pyridine compounds for inflammation and immune-related uses
WO2007114323A1 (ja) 2006-04-04 2007-10-11 Taisho Pharmaceutical Co., Ltd. アミノピロリジン化合物
CN101511840A (zh) 2006-04-26 2009-08-19 吉宁特有限公司 磷酸肌醇3-激酶抑制剂化合物及其使用方法
AU2007272956B2 (en) 2006-07-11 2013-05-02 Janssen Pharmaceutica, N.V. Benzofuro-and benzothienopyryimidine modulators of the histamine H4 receptor
US8497272B2 (en) 2006-08-21 2013-07-30 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
TWI440632B (zh) 2006-08-21 2014-06-11 Synta Pharmaceuticals Corp 用於治療增生性疾病的化合物
TW200817348A (en) 2006-08-21 2008-04-16 Synta Pharmaceuticals Corp Compounds for the treatment of proliferative disorders
US8779154B2 (en) 2006-09-26 2014-07-15 Qinglin Che Fused ring compounds for inflammation and immune-related uses
WO2008057246A2 (en) 2006-10-26 2008-05-15 Synta Pharmaceuticals Corp. Method for treating inflammatory disorders
CA2669695C (en) 2006-11-13 2012-10-30 Synta Pharmaceuticals Corp. Tetrahydropyridinyl compounds for inflammation and immune-related uses
EP2129219A4 (en) 2007-02-16 2012-08-29 Synta Pharmaceuticals Corp SUBSTITUTED FUSED CYCLE COMPOUNDS USED IN CASES OF INFLAMMATION OR IMMUNE DISORDERS
WO2008132502A1 (en) 2007-04-25 2008-11-06 Astrazeneca Ab Pyrazolyl-amino-substituted pyrimidines and their use for the treatment of cancer
US8093425B2 (en) 2007-04-30 2012-01-10 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
MX2009012719A (es) 2007-05-24 2010-02-04 Vertex Pharma Tiazoles y pirazoles utiles como inhibidores de cinasa.
WO2009007753A2 (en) 2007-07-11 2009-01-15 Astrazeneca Ab 4- (3-aminopyrazole) -pyrimidine derivativee and their use as tyrosine kinase inhibitors for the treatment of cancer
KR20100038108A (ko) 2007-07-25 2010-04-12 브리스톨-마이어스 스큅 컴퍼니 트리아진 키나제 억제제
TW200906818A (en) 2007-07-31 2009-02-16 Astrazeneca Ab Chemical compounds
EP2184994B1 (en) 2007-08-01 2013-09-25 Synta Pharmaceuticals Corp. Heterocycle-aryl compounds for inflammation and immune-related uses
TW200911800A (en) 2007-08-01 2009-03-16 Synta Pharmaceuticals Corp Pyridine compounds for inflammation and immune-related uses
US8349841B2 (en) 2007-08-01 2013-01-08 Synta Pharmaceuticals Corp. Vinyl-aryl derivatives for inflammation and immune-related uses
WO2009020631A2 (en) 2007-08-07 2009-02-12 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2009023179A2 (en) 2007-08-10 2009-02-19 Genelabs Technologies, Inc. Nitrogen containing bicyclic chemical entities for treating viral infections
US8324219B2 (en) 2007-09-20 2012-12-04 Synta Pharmaceuticals Corp. Substituted benzoimidazolyl-pyrazine compounds for inflammation and immune-related uses
MX2010005950A (es) 2007-11-28 2010-06-17 Schering Corp 2-fluoropirazolo[1,5-a]pirimidinas como inhibidores de proteina quinasa.
EP2240029A4 (en) 2008-01-07 2012-08-22 Synta Pharmaceuticals Corp COMPOUNDS FOR USE AGAINST INFLAMMATORY AND IMMUNOMIC DISEASES
EP2244709A4 (en) 2008-02-07 2012-02-29 Synta Pharmaceuticals Corp TOPICAL FORMULATIONS FOR THE TREATMENT OF PSORIASIS
WO2009105257A1 (en) 2008-02-21 2009-08-27 Synta Pharmaceuticals Corp. Compounds for treating proliferative disorders
WO2010039236A1 (en) 2008-10-01 2010-04-08 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
EP2350064A1 (en) 2008-10-01 2011-08-03 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
EP2350006A1 (en) 2008-10-01 2011-08-03 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
GB2465405A (en) 2008-11-10 2010-05-19 Univ Basel Triazine, pyrimidine and pyridine analogues and their use in therapy
JP5578490B2 (ja) * 2008-12-26 2014-08-27 味の素株式会社 ピラゾロピリミジン化合物
WO2010086040A1 (en) 2009-01-29 2010-08-05 Biomarin Iga, Ltd. Pyrazolo-pyrimidines for treatment of duchenne muscular dystrophy
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
US8591943B2 (en) 2009-04-09 2013-11-26 Merck Sharp & Dohme Corp. Pyrazolo[1,5-a]pyrimidine derivatives as mTOR inhibitors
US20110071115A1 (en) 2009-09-11 2011-03-24 Cylene Pharmaceuticals, Inc. Pharmaceutically useful heterocycle-substituted lactams
WO2011081171A1 (ja) 2009-12-28 2011-07-07 味の素株式会社 スクリーニング方法
MX2012009866A (es) 2010-02-26 2012-09-12 Mitsubishi Tanabe Pharma Corp Compuestos pirazolopirimidina y su uso como inhibidores de fosfodiesterasa 10.
WO2011146727A1 (en) 2010-05-19 2011-11-24 Philip Bosch Methods of treating interstitial cystitis
US20120083498A1 (en) 2010-06-17 2012-04-05 Fatah Kashanchi Modulators of Viral Transcription, and Methods and Compositions Therewith
MA34392B1 (fr) 2010-06-24 2013-07-03 Gilead Sciences Inc Pyrimidines en tant qu'agents antiviraux
WO2012027240A1 (en) 2010-08-23 2012-03-01 Schering Corporation Fused tricyclic inhibitors of mammalian target of rapamycin
WO2012037116A2 (en) 2010-09-13 2012-03-22 The Children's Hospital Of Philadelphia Common and rare genetic variations associated with common variable immunodeficiency (cvid) and methods of use thereof for the treatment and diagnosis of the same
WO2012047569A1 (en) 2010-09-28 2012-04-12 Schering Corporation Fused tricyclic inhibitors of mammalian target of rapamycin
RU2013120966A (ru) 2010-10-08 2014-11-20 Эббви Инк. ФУРО[3,2-d]ПИРИМИДИНОВЫЕ СОЕДИНЕНИЯ
WO2012064808A1 (en) 2010-11-09 2012-05-18 Synta Pharmaceuticals Corp Tetrazolyl - tetrahydropyridine compounds for inflammation and immune - related uses
US9234885B2 (en) 2011-01-25 2016-01-12 Albert Einstein College Of Medicine, Inc. Methods and assays for treating filoviridae infections
US9493813B2 (en) 2011-02-14 2016-11-15 Beth Israel Deaconess Medical Center, Inc. Modulation of phosphatidylinositol-5-phosphate-4-kinase activity
WO2012147890A1 (ja) 2011-04-27 2012-11-01 持田製薬株式会社 新規アゾール誘導体
WO2012170827A2 (en) 2011-06-08 2012-12-13 Cylene Pharmaceuticals, Inc. Pyrazolopyrimidines and related heterocycles as ck2 inhibitors
JP5531066B2 (ja) 2011-08-24 2014-06-25 田辺三菱製薬株式会社 ピラゾロピリミジン化合物及びｐｄｅ１０阻害剤としてのその使用
WO2013028263A1 (en) 2011-08-24 2013-02-28 Glaxosmithkline Llc Pyrazolopyrimidine derivatives as pi3 kinase inhibitors
US20140242099A1 (en) 2011-10-28 2014-08-28 Synta Pharmaceuticals Corp. Compounds for inflammation and immune-related uses
CN106986869A (zh) 2012-04-17 2017-07-28 吉利德科学公司 用于抗病毒治疗的化合物和方法
CN103242341B (zh) 2013-04-19 2015-12-09 中国科学院广州生物医药与健康研究院 噻吩并2，4取代嘧啶类化合物及其药物组合物与应用
EP2857004B1 (en) 2013-10-07 2018-07-04 The Procter and Gamble Company Hair straightening method involving reducing sugars
NZ718487A (en) 2013-10-16 2020-01-31 Shanghai Yingli Pharm Co Ltd Fused heterocyclic compound, preparation method therefor, pharmaceutical composition, and uses thereof
CN106659716B (zh) 2014-01-24 2021-03-12 人工智能治疗公司 阿吡莫德组合物及其使用方法
PL407081A1 (pl) 2014-02-05 2015-08-17 Celon Pharma Spółka Akcyjna Pochodne pirazolo[1,5-a]pirymidyny jako inhibitory kinazy JAK-2
CR20160525A (es) 2014-05-14 2016-12-20 Pfizer Pirazolopiridinas y pirazolopirimidinas
HUE056957T2 (hu) 2014-08-29 2022-04-28 Chdi Foundation Inc Próbák huntingtin fehérjét megjelenítõ képalkotásra
US10206910B2 (en) 2014-11-07 2019-02-19 Lam Therapeutics, Inc. Apilimod for use in the treatment of renal cancer
CA2966334A1 (en) 2014-11-07 2016-05-12 Lam Therapeutics, Inc. Apilimod for use in the treatment of colorectal cancer
AU2015359624B2 (en) 2014-12-08 2020-01-02 Janssen Sciences Ireland Uc Piperidine substituted pyrazolo[1,5-a]pyrimidine derivatives with inhibitory activity on the replication of the respiratory syncytial virus (RSV)
WO2016112072A1 (en) 2015-01-07 2016-07-14 President And Fellows Of Harvard College Methods for treating or preventing ebolavirus or marburgvirus infections
US10729694B2 (en) 2015-01-23 2020-08-04 AI Therapeutics, Inc. Anti-viral compositions containing PIKfyve inhibitors and use thereof
US20180015098A1 (en) 2015-02-03 2018-01-18 Lam Therapeutics, Inc. Apilimod compositions and methods for using same
CN105963300B (zh) 2015-03-13 2019-06-11 中国人民解放军军事医学科学院放射与辐射医学研究所 PIKfyve抑制剂抗辐射损伤的用途
JP2018076234A (ja) 2015-03-16 2018-05-17 大正製薬株式会社 ピラゾロ［１，５−ａ］ピリミジン化合物
WO2016160102A1 (en) 2015-03-31 2016-10-06 Lam Therapeutics, Inc. Active metabolites of apilimod and uses thereof
US10710978B2 (en) 2015-03-31 2020-07-14 Dana-Farber Cancer Institute, Inc. STK4 inhibitors for treatment of hematologic malignancies
PL236355B1 (pl) 2015-04-02 2021-01-11 Celon Pharma Spolka Akcyjna Pochodne 7-(morfolin-4-ylo)pirazolo[1,5-α]pirymidyny jako inhibitory kinazy PI3
US10758545B2 (en) 2015-06-25 2020-09-01 University Of Southern California Methods to treat neurological diseases
WO2017002120A1 (en) 2015-07-02 2017-01-05 Yeda Research And Development Co. Ltd. Selective inhibitors of senescent cells and uses thereof
TWI746449B (zh) 2015-07-20 2021-11-21 美商Ａｉ治療公司 使用阿吡莫德治療癌症之方法
CN108135906A (zh) 2015-07-24 2018-06-08 路易斯维尔大学研究基金会有限公司 治病化合物、组合物、方法、及化合物制备方法
GB201514754D0 (en) 2015-08-19 2015-09-30 Karus Therapeutics Ltd Compounds
WO2017040971A1 (en) 2015-09-03 2017-03-09 Biomarin Pharmaceutical Inc. Methods of using inhibitors of pikfyve for the treatment of lysosomal storage disorders and neurodegenerative diseases
EP3352753A4 (en) 2015-09-24 2019-03-13 The Regents of The University of California SYNTHETIC SPHINGOLIPIDE-SIMILAR MOLECULES, MEDICAMENTS, METHODS FOR THEIR SYNTHESIS AND TREATMENT PROCEDURES
GB201517263D0 (en) 2015-09-30 2015-11-11 Ucb Biopharma Sprl And Katholieke Universiteit Leuven Therapeutic agents
JP2018199623A (ja) * 2015-10-22 2018-12-20 大正製薬株式会社 含窒素縮合複素環化合物
EP3380476B1 (en) 2015-11-23 2020-09-30 Council of Scientific and Industrial Research Fused pyrimidines as isoform selective phosphoinositide-3-kinase-alpha inhibitors and process for preparation thereof
US20190015421A1 (en) 2016-01-21 2019-01-17 Lam Therapeutics, Inc. Biomarkers for Treating Cancer with Apilimod
CN105820175B (zh) 2016-04-13 2019-09-20 四川大学 一种噻吩并嘧啶类化合物及其制备方法和应用
US20180036420A1 (en) 2016-08-03 2018-02-08 Lam Therapeutics, Inc. Methods for enhancing the delivery of molecules across the blood brain barrier
US20180050041A1 (en) 2016-08-19 2018-02-22 Lam Therapeutics, Inc. Compositions and Methods for Treating Niemann Pick C Disease
JP2019528305A (ja) 2016-08-25 2019-10-10 エイアイ・セラピューティクス・インコーポレーテッド ＰＩＫｆｙｖｅ阻害薬を含む組成物およびＲＡＮＫシグナル伝達の阻害に関連する方法
GB201616237D0 (en) 2016-09-23 2016-11-09 Univ Oslo Hf Modulation of function of immune effector cells
KR20190067824A (ko) 2016-10-12 2019-06-17 에이아이 테라퓨틱스, 인코포레이티드 아필리모드 조성물 및 이를 알츠하이머병 치료에 사용하기 위한 방법
KR102654864B1 (ko) 2016-11-18 2024-04-05 삼성전자주식회사 유기금속 화합물, 이를 포함한 유기 발광 소자 및 이를 포함한 진단용 조성물
JOP20190113A1 (ar) 2016-11-18 2019-05-15 Biocad Joint Stock Co مثبطات بروتون تيروزين كيناز
WO2018129536A1 (en) 2017-01-09 2018-07-12 San Diego State University (SDSU) Foundation, dba San Diego State University Research Foundation Therapeutic and immunomodulatory bacteriophage formulations and methods for making and using them
US10021905B1 (en) 2017-01-17 2018-07-17 Modern Vital Inc. Smoking apparatus with a pump and a method of using same
US20190070166A1 (en) 2017-09-02 2019-03-07 Richard Postrel Optimized Method for Treating and Curing Arthritis, Diabetes, Multiple Sclerosis and Other Autoimmune Disease
WO2018138106A1 (en) 2017-01-27 2018-08-02 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for the treatment of heart failure
CN106957303B (zh) 2017-02-28 2019-06-04 中山大学 选择性Aurora A激酶抑制活性的喹唑啉衍生物及其制备方法以及应用
US11066410B2 (en) 2017-03-24 2021-07-20 3100 Central Expressway Llc Fused triazolo-pyrimidine compounds having useful pharmaceutical application
US10702534B2 (en) 2017-03-31 2020-07-07 AI Therapeutics, Inc. Compositions and methods relating to the radioprotective effects of apilimod
CN107163061A (zh) 2017-04-14 2017-09-15 江西科技师范大学 含吡唑啉结构的噻吩并嘧啶类化合物的制备及应用
WO2018226150A1 (en) 2017-06-05 2018-12-13 Medivir Aktiebolag Pyrazolopyrimidine as malt-1 inhibitors
AR112027A1 (es) 2017-06-15 2019-09-11 Biocryst Pharm Inc Inhibidores de alk 2 quinasa que contienen imidazol
US12291533B2 (en) 2017-08-02 2025-05-06 Northwestern University Substituted fused pyrimidine compounds and uses thereof
CN109384782A (zh) 2017-08-04 2019-02-26 厦门大学 取代五元并六元杂环类化合物、其制备方法、药物组合及其用途
WO2019046316A1 (en) * 2017-08-28 2019-03-07 Acurastem Inc. PIKFYVE KINASE INHIBITORS
WO2019108665A1 (en) 2017-12-01 2019-06-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Autophagy modulators for use in treating cancer
WO2019113523A1 (en) 2017-12-08 2019-06-13 Ashok Bajji Compounds and therapeutic uses thereof
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
AU2019223014B2 (en) 2018-02-21 2024-10-17 Orphai Therapeutics Inc. Combination therapy with apilimod and glutamatergic agents
EP3784351A1 (en) 2018-04-27 2021-03-03 Novartis AG Car t cell therapies with enhanced efficacy
AU2019291491B2 (en) 2018-06-19 2020-05-21 Armaceutica, Inc Bifunctional compositions for the treatment of cancer
CN108586486B (zh) 2018-06-19 2021-03-02 四川大学 一种芳基取代噻吩并嘧啶类化合物的制备方法
EP3817736A4 (en) 2018-07-05 2021-07-28 Mayo Foundation for Medical Education and Research PIKFYVE INHIBITORS
GB2576039B (en) 2018-08-02 2021-01-06 Ip2Ipo Innovations Ltd A joint
CN110835345A (zh) 2018-08-17 2020-02-25 中国科学院上海药物研究所 一类细胞周期依赖性激酶的降解剂、其制备方法、药物组合物及其用途
US20210033597A1 (en) 2018-12-31 2021-02-04 AcuraStem Incorporated Method for identifying effective treatments against neurodegenerative disorders
US20220144838A1 (en) 2019-03-13 2022-05-12 Nanjing Immunophage Biotech Co., Ltd. Compounds as Inhibitors of Macrophage Migration Inhibitory Factor
JP2022526012A (ja) 2019-04-10 2022-05-20 コーネル・ユニバーシティー Ｐｉｐ４ｋにより触媒非依存性機構を介してインスリンシグナル伝達を抑制し、免疫機能を増強させる方法
CN112142744A (zh) 2019-06-28 2020-12-29 上海瑛派药业有限公司 取代的稠合杂芳双环化合物作为激酶抑制剂及其应用
US20210077500A1 (en) 2019-09-12 2021-03-18 Al Therapeutics, Inc. Pikfyve inhibitors for cancer therapy
KR102938141B1 (ko) 2019-11-08 2026-03-11 벤틱스 바이오사이언스, 인크. Tyk2 슈도키나제 리간드
CA3158256A1 (en) 2019-11-13 2021-05-20 Aimee EDINGER Drug formulations and methods of treatment for metabolic disorders
US20230038929A1 (en) 2019-12-05 2023-02-09 Verge Analytics, Inc. Fused Tricyclic Heterocyclic Compounds and Uses Thereof
KR20220140515A (ko) 2020-01-13 2022-10-18 버지 애널리틱스, 인크. 치환된 피라졸로-피리미딘 및 그의 용도
WO2021151100A1 (en) 2020-01-24 2021-07-29 Aim Immunotech Inc. Methods, compositions, and vaccines for treating a virus infection
WO2021155067A1 (en) 2020-01-28 2021-08-05 University Of Southern California Compositions and methods to treat neurological diseases
EP4100016A1 (en) 2020-02-07 2022-12-14 AI Therapeutics, Inc. Anti-viral compositions and methods of use
WO2021163727A1 (en) 2020-02-11 2021-08-19 AcuraStem Incorporated Pikfyve kinase inhibitors
EP4118087A1 (en) 2020-03-09 2023-01-18 Verge Analytics, Inc. Substituted furo[3,2-d]pyrimidines and uses thereof
US11806359B2 (en) 2020-03-31 2023-11-07 Phoenix Biotechnology, Inc. Method and compositions for treating Coronavirus infection
US20210338683A1 (en) 2020-05-01 2021-11-04 AcuraStem, Inc. Treatment of viral infections with combination of pikfyve kinase inhibitors and tmprss-2 inhibitors
EP4161926A4 (en) 2020-06-03 2024-06-19 Yumanity Therapeutics, Inc. PYRIDOPYRIMIDINES AND THEIR METHODS OF USE
EP4161519A4 (en) 2020-06-03 2024-07-17 Yumanity Therapeutics, Inc. PURINES AND METHODS OF USE
WO2021247862A1 (en) 2020-06-03 2021-12-09 Yumanity Therapeutics, Inc. Bicyclic heteroarenes and methods of their use
US20240016810A1 (en) 2020-06-11 2024-01-18 Kineta, Inc. Compositions and methods for the treatment and prevention of neurological disorders
TW202202506A (zh) 2020-07-13 2022-01-16 中國商北京泰德製藥股份有限公司 作為atr激酶抑制劑的吡唑並嘧啶化合物
US20240018151A1 (en) 2020-10-19 2024-01-18 Tme Therapeutics Llc Novel inhibitors of pikfyve and methods using same
WO2022094058A1 (en) 2020-10-28 2022-05-05 The Regents Of The University Of Michigan Methods for preventing or treating conditions related to pikfyve activity
WO2022094615A1 (en) 2020-10-29 2022-05-05 The Regents Of The University Of California Compounds and methods for increased antisense activity
CA3217458A1 (en) 2021-05-06 2022-11-10 Spyro Mousses Sirna constructs for inhibiting gene expression in targeted cancer cells
EP4351585A1 (en) 2021-06-11 2024-04-17 Orphai Therapeutics Inc. Stabilized apilimod compositions and uses thereof
IL309445A (en) 2021-06-22 2024-02-01 Acurastem Inc PIKFYVE antisense oligonucleotides

Also Published As

Publication number Publication date
WO2021146192A1 (en) 2021-07-22
EP4090426A1 (en) 2022-11-23
KR20220140515A (ko) 2022-10-18
CN115209952B (zh) 2025-05-30
MX2022008627A (es) 2022-11-08
PH12022551623A1 (en) 2023-11-29
CA3167339A1 (en) 2021-07-22
AU2021207804A1 (en) 2022-09-01
US20230133203A1 (en) 2023-05-04
CN115209952A (zh) 2022-10-18
JP2023510874A (ja) 2023-03-15
TWI885039B (zh) 2025-06-01
IL294504A (en) 2022-09-01
CO2022011258A2 (es) 2022-09-30
JP7744350B2 (ja) 2025-09-25
TW202140483A (zh) 2021-11-01
EP4090426B1 (en) 2025-12-31
US12486274B2 (en) 2025-12-02
CL2022001887A1 (es) 2023-04-10

Similar Documents

Publication Publication Date Title
BR112022013488A2 (pt) Pirazolo-pirimidinas substituídas e seu uso
BR112022000064A2 (pt) Inibidores de hpk1 e usos dos mesmos
ECSP22087539A (es) Inhibidores de kras tricíclicos fusionados
BR112021023824A8 (pt) Composto, composição farmacêutica, método para inibir dna-pk e uso do composto ou da composição farmacêutica
BR112015015635A8 (pt) composto, método de preparação dos compostos, composição farmacêutica e método in vitro de previsão
BR112018070677A2 (pt) inibidores de mcl-1 macrocíclicos para o tratamento de câncer
MX2025001016A (es) Derivados de piperidinilpiridinilcarbonitrilo como inhibidores de glutaminil-peptido ciclotransferasa y proteina tipo glutaminil-peptido ciclotransferasa
BR112021026820A2 (pt) Inibidores heterocíclicos de monoacilglicerol lipase (magl)
JOP20250215A1 (ar) ثيازولو[4،5-d]-بيريميدين-7-ونات كمثبطات NOX4
BR112022025117A2 (pt) 2-amino-3-fluoro-but-3-enamidas macrocíclicas como inibidores de mcl-1
MX2023015436A (es) Inhibidores de cdk2 y metodos de uso de los mismos.
BR112023015425A2 (pt) Derivados de uracila como inibidores de trpa1
CL2023000837A1 (es) Derivados de tetrazol como inhibidores de trpa1
MX2024011755A (es) Derivados sulfonamidicos como inhibidores de la cinasa dependiente de ciclina 2 (cdk2)
AR124449A1 (es) Inhibidores de sos1 y usos de los mismos
CL2023000838A1 (es) Derivados de tetrazol como inhibidores de trpa1
BR112023015342A2 (pt) Derivados de 3h,4h-[2,3-d]-pirimidin-4-ona como inibidores de trpa1
CL2025001665A1 (es) Derivados de tiadiazolilo como inhibidores de adn polimerasa theta y sus usos
CL2021000282A1 (es) Inhibidores de ckd8/19
CO2025016647A2 (es) Inhibidores de egfr para el tratamiento de enfermedades
DOP2022000270A (es) Derivados de tetrazol como inhibidores de trpa1
CL2022003329A1 (es) Derivados de tetrazol como inhibidores de trpa1
CO2023000858A2 (es) Inhibidores de atr y usos de estos
AR132890A1 (es) Aminas bicíclicas como inhibidores de cdk2
UY38133A (es) Nuevos inhibidores de cdk8/19

Legal Events

Date Code Title Description
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements